Short communication
Measurement of HBsAg to monitor hepatitis B viral replication in patients on α-interferon therapy

https://doi.org/10.1016/0166-3542(94)90022-1Get rights and content

Abstract

HBsAg was measured quantitatively in serum samples collected serially before and after the HBeAg seroconversion date from 69 patients with HBeAg seroconversion and 17 patients with both HBeAg and HBsAg seroconversion. In patients with only HBeAg seroconversion the median HBsAg level decreased from 8.39 μg/ml (range 0.01–57.51) before HBeAg seroconversion to 3.53 μg/ml (range 0.002–68.66) after seroconversion (P < 0.001). No significant drop in HBsAg was found for the control group (18 HBeAg-positive patients without seroconversion). From 12 other patients on α-interferon therapy HBsAg was quantitatively assayed monthly during and after therapy; HBsAg levels were compared to the levels of HBV-DNA and HBeAg. We observed a good correlation between the HBsAg level and both the HBV-DNA (r = 0.76; P < 0.001) and the HBeAg (r = 0.70; P < 0.001) level, irrespective of the response to α-interferon. Quantified assessment of HBsAg appears promising as a simple and cheap method for monitoring viral replication in chronic hepatitis B in patients undergoing interferon therapy.

References (13)

There are more references available in the full text version of this article.

Cited by (52)

  • The role of quantitative hepatitis B surface antigen revisited

    2017, Journal of Hepatology
    Citation Excerpt :

    Discrepant findings (i.e., a virologic profile of inactive carrier, but elevated liver stiffness values) should prompt further investigation to rule out either an intermittent viral replication responsible for CHB or a liver disease of other etiology. Several studies have shown that the change of serum HBsAg levels during PegIFN therapy mimics the change of both intrahepatic cccDNA and intrahepatic HBsAg, suggesting that a decline in serum HBsAg levels is associated with the induction of an effective anti-HBV immune response [2,56–58]. Therefore, HBsAg levels are a valuable tool for the monitoring of patients treated with PegIFN.

  • Focus

    2013, Journal of Hepatology
  • HBsAg quantification to predict natural history and treatment outcome in chronic hepatitis B patients

    2013, Clinics in Liver Disease
    Citation Excerpt :

    The HBeAg seroconversion rate was observed in 32% in HBeAg(+) patients29 and an HBV DNA less than 400 IU/mL in 19% in HBeAg(−) patients.30 In the early 1990s, HBsAg quantification was already considered to be a promising, simple, and inexpensive method to monitor viral replication in CHB patients who were receiving IFN treatment.31 More recently, the availability of well-standardized commercial assays has renewed interest in the quantitative serum HBsAg as a biomarker for treatment response in CHB.9,10

  • Hepatitis B surface antigen quantification: A new virologic fal for monitoring of chronic hepatitis B

    2012, Revue Francophone des Laboratoires
    Citation Excerpt :

    L’intérêt de la quantification de l’AgHBs pour le suivi des réponses aux traitements à base d’IFN chez les patients AgHBe positifs a été proposé en 1994, lorsqu’une baisse significative du titre d’AgHBs a été observée chez les patients répondeurs à l’IFN avec séroconversion HBe, mais non chez les patients sans séroconversion [12]. Ainsi la quantification de l’AgHBs a été proposée comme moyen de surveillance [12]. Cependant le manque de standardisation des tests de quantification disponibles a empêché sa large diffusion jusqu’à récemment.

View all citing articles on Scopus
View full text